Letters by company

Takeda Pharmaceutical CO LTD

1 letter discussing TAK. Everything written about it on this site is on its ticker page.

Polaris Capital Management Third Quarter 2026 International Equity Composite Commentary Polaris International Equity Composite made no purchases or sales, backing resilient cash-generative businesses as higher rates and fiscal deficits threaten concentrated, AI-led equity markets. It discusses financials supported by widening lending margins and memory-chip holdings SK hynix and Samsung amid AI-spending doubts despite strengthening fundamentals. Third Quarter 2026 DNBBF $48BMUFG $253BSB1NO